Matthew Growdon's guest appearances

Matthew Growdon

GeriPal

Navigating Neuropsychology

Mike Steinman

BJ Miller

Andy Cohen

Aaron Kesselheim

Simon Baron-Cohen

Louise Aronson

Bruce Miller

Haider Warraich

Lewis Cohen

Stephanie Rogers

Tim Anderson

Jessica Zitter

Susan Block

John Mills

Katie Fitzgerald

OwlTail

In this episode, we speak with Dr. Matthew Growdon about medications for memory loss in older adults. We cover cholinesterase inhibitors for memory loss in older adults, their efficacy in Alzheimer’s dementia as well as other dementia etiologies, their efficacy in mild cognitive impairment, the NMDA receptor antagonist memantine, combination therapies, how to talk to patients about these medications, how to write about them in neuropsych reports, and we end with a brief discussion of aducanumab. Show notes are available at www.NavNeuro.com/97 _____ If you’d like to support the show, here are a few easy ways: 1) Get APA-approved CE credit for listening to select episodes: www.NavNeuro.com/INS  2) Tell your friends and colleagues about it 3) Subscribe (free) and leave an Apple Podcasts rating/review: www.NavNeuro.com/itunes 4) Contribute to the discussion in the comments section of the website (click the episode link listed above) or on Twitter (@NavNeuro)   Thanks for listening, and join us next time as we continue to navigate the brain and behavior! [Note: This podcast and all linked content is intended for general educational purposes only and does not constitute the practice of psychology or any other professional healthcare advice and services. No professional relationship is formed between hosts and listeners. All content is to be used at listeners’ own risk. Users should always seek appropriate medical and psychological care from their licensed healthcare provider.]

In this episode, we speak with Dr. Matthew Growdon about medications for memory loss in older adults. We cover cholinesterase inhibitors for memory loss in older adults, their efficacy in Alzheimer’s dementia as well as other dementia etiologies, their efficacy in mild cognitive impairment, the NMDA receptor antagonist memantine, combination therapies, how to talk to patients about these medications, how to write about them in neuropsych reports, and we end with a brief discussion of aducanumab. Show notes are available at <a href="http://www.navneuro.com/97" rel="nofollow" target="_blank">www.NavNeuro.com/97</a> _____ If you’d like to support the show, here are a few easy ways: 1) Get APA-approved CE credit for listening to select episodes: <a href="http://www.navneuro.com/INS" rel="nofollow" target="_blank">www.NavNeuro.com/INS</a> 2) Tell your friends and colleagues about it 3) Subscribe (free) and leave an Apple Podcasts rating/review: <a href="http://www.navneuro.com/itunes" rel="nofollow" target="_blank">www.NavNeuro.com/itunes</a> 4) Contribute to the discussion in the comments section of the website (click the episode link listed above) or on Twitter (@NavNeuro) Thanks for listening, and join us next time as we continue to navigate the brain and behavior! [Note: This podcast and all linked content is intended for general educational purposes only and does not constitute the practice of psychology or any other professional healthcare advice and services. No professional relationship is formed between hosts and listeners. All content is to be used at listeners’ own risk. Users should always seek appropriate medical and psychological care from their licensed healthcare provider.]

97| Medications for Memory Loss in Older Adults – With Dr. Matthew Growdon

Today we discuss polypharmacy and deprescribing with two geriatricians.  We cover definitions of polypharmacy, inappropriate polypharmacy, deprescribing as an intervention, specific drug classes with potential for cognitive side effects in older adults, and a neuropsychologist’s role in clinical care related to polypharmacy.   Show notes are available at www.NavNeuro.com/96 _____ If you’d like to support the show, here are a few easy ways: 1) Get APA-approved CE credit for listening to select episodes: www.NavNeuro.com/INS  2) Tell your friends and colleagues about it 3) Subscribe (free) and leave an Apple Podcasts rating/review: www.NavNeuro.com/itunes 4) Contribute to the discussion in the comments section of the website (click the episode link listed above) or on Twitter (@NavNeuro)   Thanks for listening, and join us next time as we continue to navigate the brain and behavior! [Note: This podcast and all linked content is intended for general educational purposes only and does not constitute the practice of psychology or any other professional healthcare advice and services. No professional relationship is formed between hosts and listeners. All content is to be used at listeners’ own risk. Users should always seek appropriate medical and psychological care from their licensed healthcare provider.]

Today we discuss polypharmacy and deprescribing with two geriatricians.  We cover definitions of polypharmacy, inappropriate polypharmacy, deprescribing as an intervention, specific drug classes with potential for cognitive side effects in older adults, and a neuropsychologist’s role in clinical care related to polypharmacy. Show notes are available at <a href="http://www.navneuro.com/96" rel="nofollow" target="_blank">www.NavNeuro.com/96</a> _____ If you’d like to support the show, here are a few easy ways: 1) Get APA-approved CE credit for listening to select episodes: <a href="http://www.navneuro.com/INS" rel="nofollow" target="_blank">www.NavNeuro.com/INS</a> 2) Tell your friends and colleagues about it 3) Subscribe (free) and leave an Apple Podcasts rating/review: <a href="http://www.navneuro.com/itunes" rel="nofollow" target="_blank">www.NavNeuro.com/itunes</a> 4) Contribute to the discussion in the comments section of the website (click the episode link listed above) or on Twitter (@NavNeuro) Thanks for listening, and join us next time as we continue to navigate the brain and behavior! [Note: This podcast and all linked content is intended for general educational purposes only and does not constitute the practice of psychology or any other professional healthcare advice and services. No professional relationship is formed between hosts and listeners. All content is to be used at listeners’ own risk. Users should always seek appropriate medical and psychological care from their licensed healthcare provider.]

96| Polypharmacy in Older Adults – With Dr. Mike Steinman and Dr. Matthew Growdon

Anna Parks

In a new study in  JAGS, Matthew Growdon found that the average number of medications people with dementia took in the outpatient setting was eight, compared to 3 for people without dementia.   In another study in  JAGS, Anna Parks found that among older adults with atrial fibrillation, less than 10% of disability could be explained by stroke over an almost 8 year time period.  She also talked about the need for a new framework for anti-coagulation decisions for patients in the last 6 months of life, based on an article she authored in  JAMA Internal Medicine with Ken Covinsky. In today’s podcast we talk with Matthew and Anna, joined by co-author Mike Steinman, to talk about polypharmacy, deprescribing, where we are and what we need to do to stop this freight train of ever more medications for older adults and those living with serious illness. We start by addressing the root cause of the problem.  Clinicians want to “do something” to help their patients.  And one thing we know how to do is prescribe.  It’s much harder psychologically for clinicians to view deprescribing a medication as “doing something.”  This attitude needs to change.  It will take teamwork to get there, with robust involvement of pharmacists, and likely activating patients to advocate for themselves. And Eric might have mentioned aducanumab a time or two… -AlexSmithMD

In a new study in <a href="https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.17291" rel="nofollow" target="_blank"> JAGS</a>, Matthew Growdon found that the average number of medications people with dementia took in the outpatient setting was eight, compared to 3 for people without dementia.   In another study in <a href="https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.17291" rel="nofollow" target="_blank"> JAGS</a>, Anna Parks found that among older adults with atrial fibrillation, less than 10% of disability could be explained by stroke over an almost 8 year time period.  She also talked about the need for a new framework for anti-coagulation decisions for patients in the last 6 months of life, based on an article she authored in <a href="https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2779426" rel="nofollow" target="_blank"> JAMA</a> Internal Medicine with Ken Covinsky. In today’s podcast we talk with Matthew and Anna, joined by co-author Mike Steinman, to talk about polypharmacy, deprescribing, where we are and what we need to do to stop this freight train of ever more medications for older adults and those living with serious illness. We start by addressing the root cause of the problem.  Clinicians want to “do something” to help their patients.  And one thing we know how to do is prescribe.  It’s much harder psychologically for clinicians to view deprescribing a medication as “doing something.”  This attitude needs to change.  It will take teamwork to get there, with robust involvement of pharmacists, and likely activating patients to advocate for themselves. And Eric might have mentioned aducanumab a time or two… -AlexSmithMD

Polypharmacy and Deprescribing Super Special: Podcast with Anna Parks, Matthew Growdon, and Mike Steinman